Background. Two antibiotic regimens are used commonly in Thailand for the initial treatment of severe melioidosis: ceftazidime in combination with trimethoprim-sulfamethoxazole (TMP-SMX) and ceftazidime monotherapy. It is not known whether TMP-SMX provides an additional benefit.
ical manifestations are protean, but the most frequent presenting clinical presentation among affected individuals in this region is a septicemic illness, which is often associated with bacterial dissemination to distant sites. B. pseudomallei is also an important pathogen in the Northern Territory of Australia, where it is the most common cause of fatal community-acquired pneumonia [2] . B. pseudomallei is listed as a category B disease/bioterrorist threat agent by the US Centers for Disease Control and Prevention.
Previous treatment trials have demonstrated the importance of the choice of antibiotic at the time of presentation. Studies that compared a 4-drug combination of chloramphenicol, doxycycline, and trimethoprim-sulfamethoxazole (TMP-SMX; this was standard therapy in Thailand before 1988) with ceftazidime alone [3] or ceftazidime plus TMP-SMX [4] demonstrated a 50% reduction in the mortality rate for patients with severe melioidosis who received either ceftazidime-containing regimen. It is unclear whether the addition of TMP-SMX to ceftazidime therapy confers an additional benefit over ceftazidime monotherapy. The use of TMP-SMX may lead to an increased number of adverse effects, and there is in vitro evidence to suggest that TMP-SMX antagonizes the bactericidal activity of ceftazidime [5] . Here, we report the results of 2 large prospective, randomized treatment trials comparing the therapeutic efficacy of ceftazidime alone and ceftazidime with TMP-SMX for patients with acute, severe melioidosis.
PATIENTS AND METHODS
Two prospective, randomized trials that compared ceftazidime in combination with TMP-SMX and ceftazidime monotherapy in patients who presented with acute, severe melioidosis were started independently in 1999 at Sappasithiprasong Hospital (Ubon Ratchathani, Thailand) and Srinagarind Hospital (Khon Kaen, Thailand). The studies were continued until October 2003, with patient recruitment taking place during the rainy season of June to November in each study year (a reflection of disease seasonality). The studies were approved by the Ministry of Public Health, Royal Government of Thailand, and Khon Kaen University Ethics Committee for Human Research.
The 2 studies were initiated independently and were both designed to answer a question commonly under discussion in the melioidosis research community. The protocols were similar, because they were both based on the entry criteria and study design used in previously published melioidosis trials conducted in northeast Thailand. The decision to combine data from the 2 trials in a prospective meta-analysis was made by the principal investigators once the groups had discovered the existence of each other's studies. This decision was initiated by the investigators; ethics committees and drug suppliers played no role.
All adult patients (age, 114 years) with suspected severe melioidosis were eligible for enrollment in the trials if they or their attending relatives provided consent. Severe melioidosis was defined as the presence of у2 of the following characteristics: (1) temperature, 138ЊC or !36ЊC; (2) pulse rate, 190 beats/ min; (3) respiratory rate, 120 breaths/min, or partial pressure of CO 2 , arterial, !32 mm Hg; (4) WBC count, 1 6 12,000 ϫ 10 cells/L, or band forms, 110%; (5) organ dysfunction (as defined by oliguria, mental change, or lactic acidosis); and (6) hypotension (systolic blood pressure, !90 mm Hg). Exclusion criteria in both trials were known hypersensitivity to penicillins, cephalosporins, trimethoprim, or sulfa group drugs; receipt of treatment for 124 h with an antibiotic active against B. pseudomallei, with clinical evidence of response to treatment; known infection with an isolate of ceftazidime-resistant B. pseudomallei; known HIV seropositivity; and pregnancy or lactation. Patients with aplastic anemia or glucose-6-phosphase dehydrogenase deficiency and those with a serum creatinine level of 1530 mmol/L were also excluded from the study at Ubon Ratchathani but not in Khon Kaen.
Detailed medical history and physical examination findings were recorded at the time of hospital admission using standardized forms. Baseline investigations were complete blood cell count; determination of plasma glucose, lactate, and electrolyte concentrations; and renal and liver function tests. Microbiological samples obtained from all patients before the start of antibiotic treatment were 2 blood samples (for culture) and a throat swab specimen; urine, pus, and sputum samples were obtained when available. Chest radiography was performed on the day of hospital admission for all patients, and abdominal ultrasonography was performed as clinically indicated.
All patients in both centers received ceftazidime (120 mg/kg per day; 2 g t.i.d. by bolus intravenous injection or adjusted for renal function). In Ubon Ratchathani, randomization was performed in blocks of 10 using a computer-generated randomized sequence, and the drugs were prepackaged in sealed boxes labeled with the study code. Patients were randomly allocated to receive either TMP-SMX (160/800 mg infused over 30 min every 8 h or adjusted for renal function) or placebo (0.9% normal saline, identical in appearance to ampoules of TMP-SMX). The study doctors and patients were blinded to the treatment. In Khon Kaen, the study was performed as an open-label trial with treatment allocations maintained in sealed envelopes that were opened at the point of patient enrollment. Dosing of TMP-SMX was identical to that used in Ubon Ratchathani.
Vital signs were recorded every 4 h, and a detailed clinical examination was performed daily. Supportive care and additional investigation was undertaken as clinically indicated. Abscesses were drained wherever possible. Patients who were culture negative for melioidosis after a minimum of 5 days were switched to an alternative antibiotic therapy, as appropriate, and were observed to document study end points.
Patients received parenteral therapy until they showed definite clinical evidence of improvement (usually after at least 10 days). Surviving patients in Ubon Ratchathani were then randomized as part of an independent trial of oral therapy to receive doxycycline and TMP-SMX, with or without chloramphenicol (total course, 20 weeks). Surviving patients in Khon Kaen were treated with doxycycline and TMP-SMX or with amoxicillin/clavulanate for at least 20 weeks.
The major end points were (1) in-hospital death (or discharge of the patient while moribund at the request of the family); (2) other indicators of treatment failure, as defined by (a) development of septic shock (systolic blood pressure, !90 mm Hg, with the lack of response to fluid replacement) at least 72 h after the start of treatment with the study antibiotic, (b) B. pseudomallei bacteremia after у7 days of antibiotic treatment, and (c) switch of therapy у72 h after commencement of treatment in response to clinical failure (persistent fever or new foci of infection that developed during treatment). Persistent isolation of B. pseudomallei at existing sites and persistence of radiographic abnormalities in the absence of definite clinical evidence of deterioration were not regarded as indications of treatment failure, because previous studies have shown that both are common despite good clinical response [3] .
Microbiological specimens were processed as described elsewhere [3] . Blood cultures were repeated after 24 h, 72 h, and 7 days for all patients and after 14 and 28 days of antibiotic treatment for patients with у1 positive blood culture result. Positive admission cultures of specimens from other sites were repeated weekly until negative or until the patient was discharged from hospital in Ubon Ratchathani but not in Khon Kaen. B. pseudomallei was identified as described elsewhere [6] . Antimicrobial susceptibilities were determined by the KirbyBauer disk diffusion method. TMP-SMX susceptibility testing by the disk diffusion method overestimates resistance [7] , and patients were not excluded if the disk test indicated that the infecting isolate was drug resistant. TMP-SMX susceptibility has subsequently been determined by Etest for all Ubon Ratchathani isolates. Interpretive standards for this were based on NCCLS guidelines for B. pseudomallei [8] , with TMP-SMX sensitivity defined as an MIC of р2/38 mg/mL and resistance defined as an MIC of у4/76 mg/mL.
The results were analyzed in both intention-to-treat and perprotocol analyses (for cases of culture-confirmed melioidosis) and are reported for each study site. Heterogeneity between the study sites was assessed for all variables to determine whether pooling of data was feasible. Homogeneous data were combined, and stratified P values are shown, whereas P values for each site are shown separately in brackets for heterogeneous data. Continuous data were compared by means of the KruskalWallis test for each site, and conditional logistic regression was used for combined sites. Categorical data were compared using the x 2 test or Fisher's exact test for each site, and the MantelHaenszel test was used for combined sites. Survival analysis was performed using the Kaplan-Meier method, with groups compared using the log-rank test, Wilcoxon test, or Cox regression, as appropriate. Multiple conditional logistic regression (forward Table 1 . Baseline characteristics of and mortality among 449 patients enrolled in a study of severe melioidosis, by study site. selection) was performed to evaluate factors associated with death and treatment failure for combined data. All analyses were performed using the statistical computing package Stata/ SE, version 8.0 for Windows (Stata), and SPSS for Windows, version 11.0 (SPSS).
The study was terminated when combined enrollment reached the higher of the intended enrollments calculated from a priori power calculations. At Ubon Ratchathani, the investigators intended to enroll 445 patients with suspected melioidosis, which would have 90% power to detect a reduction in the mortality rate among culture-positive patients from 35% to 17.5% (assuming that two-thirds of the enrolled patients were culture positive). At Khon Kaen, the investigators believed that 300 patients with suspected melioidosis should be enrolled, giving an 80% power to detect a reduction in the mortality rate among culture-positive patients from 40% to 20% (assuming that 60% of the enrolled patients were culture positive).
RESULTS
A total of 449 patients were enrolled, of which 232 were from Khon Kaen and 217 were from Ubon Ratchathani. A flow diagram of patient enrollment, diagnoses, and randomization is shown in figure 1 . Of these patients, 241 (37.5%) had cultureconfirmed melioidosis, of whom 87 (36.1%) were from Khon Kaen and 154 (71.0%) were from Ubon Ratchathani. Melioidosis was either excluded or not confirmed for 208 patients, of whom 33 (15.9%) had bacteremia or fungemia due to other organisms, as follows: Escherichia coli, 7 patients; Klebsiella pneumoniae, 9; Staphylococcus aureus, 7; Salmonella species, 3; Streptococcus pyogenes, 1; Acinetobacter species, 1; Enterococcus species, 1; Pseudomonas aeruginosa, 2; Penicillium marneffei, 1; and Cryptococcus neoformans, 1.
Overall, 223 patients received ceftazidime alone (118 of whom had culture-confirmed melioidosis), and 226 patients received ceftazidime and TMP-SMX (123 of whom had cultureconfirmed melioidosis). Baseline data for all patients are shown in table 1, and baseline data for patients with melioidosis are shown in tables 2 and 3. The distributions of underlying comorbidities, physical examination findings, and most laboratory parameters were similar for patients in both treatment arms, with the exception that the median serum bicarbonate level was lower in the ceftazidime monotherapy group in Ubon Blood culture results were positive for 140 (58.1%) of the patients with melioidosis; a higher proportion of patients in the ceftazidime monotherapy group were bacteremic (65.3% vs. 51.2%; stratified ). Eighty-one (34%) of 241 patients P p .03 with culture-confirmed melioidosis had positive blood culture results in association with either a single or no identifiable focus of infection (i.e., septicemic disease), 59 (24%) had positive blood culture results with multiple noncontiguous foci of infection (i.e., disseminated disease), 72 (30%) had negative blood culture results and a single focus of infection (i.e., localized disease), and 29 (12%) had negative blood culture results with multiple noncontiguous foci of infection (i.e., multifocal disease). These patients were evenly distributed between treatment groups.
Mortality. Overall, 116 patients died (25.8%) ( Among the 241 patients with melioidosis, there was no dif- figure 2 ). Treatment group was not a predictor of outcome (OR, 0.92; 95% CI, 0.4-2.1; stratified ) in multiple con-P p .83 ditional logistic regression analysis that adjusted for age, underlying disease, alteration of consciousness, dyspnea, the presence of bacteremia, lung involvement, septic shock, respiratory failure, and renal failure. In the final model, bacteremia (OR, ) were each independently asso-P ! .001 ciated with mortality.
Treatment failure. There were no differences between treatment groups with regard to the incidence of shock (stratified ) and of persistent bacteremia (stratified ). P p .45 P p .06 There were more switches in therapy in the ceftazidime monotherapy group than in the ceftazidime-TMP-SMX group (stratified ) (table 4) . Survival analysis that censored pa-P p .049 tients who died confirmed this difference (stratified , P p .05 by log rank test), but in Cox regression analysis, which adjusted for the presence of bacteremia at the time of hospital admission, there were no differences in treatment switches between the 2 groups (hazard ratio, 0.45; 95% CI, 0.19-1.11; stratified P p ). .08
There was no difference in the combined outcome of death and treatment failure between the 2 treatment groups (stratified , by the Wilcoxon test) (figure 3 ) were independently asso-P p .001 ciated with the combined outcome of mortality or treatment failure.
Adverse events. Both treatments were well tolerated. Four patients in the ceftazidime-TMP-SMX group and 2 patients in the ceftazidime monotherapy group developed a widespread erythematous rash during treatment (stratified ). This P p .48 was sufficiently severe to warrant a switch of therapy for only 1 patient, who had received TMP-SMX. Hyperkalemia in association with renal impairment developed in a similar proportion of patients in the ceftazidime-TMP-SMX group and the ceftazidime monotherapy group (11 patients [8.9%] vs. 6 patients [5.2%]; stratified ). P p .17 Complications of severe melioidosis were common: 52 patients (21%) developed septic shock, and 48 (19.9%) developed acute renal failure. One hundred thirty-three patients (55.2%) developed anemia (i.e., the hemoglobin level decreased by 11 g/dL from baseline), of whom 79 (32.8%) underwent transfusion. There were no significant differences between the 2 treatment groups for any of these variables.
Antimicrobial susceptibility of B. pseudomallei. There were 144 clinical isolates recovered from the 154 patients in Ubon Ratchathani available for TMP-SMX susceptibility testing by Etest; isolates from the Khon Kaen study were not stored. Resistance to TMP-SMX was detected in 18 isolates (12.5%) recovered from 18 patients, of whom 6 (8.6%) of 70 tested strains were in the ceftazidime only group and 12 (16.2%) of 74 tested strains were in the ceftazidime-TMP-SMX group ( ). When these patients were removed from the analysis, P p .17 there was no significant difference in treatment failure between the 2 treatment groups (10 [16.7%] of 60 patients in the ceftazidime monotherapy group and 9 [14.5%] of 62 patients in the ceftazidime-TMP-SMX group;
). There were no P p .74 differences in the percentages of drug-resistant strains between subjects who experienced treatment failure or had a late death and survivors who did not experience treatment failure when considering both treatment arms (7 [20 ). P p .69
DISCUSSION
Several studies of severe melioidosis have been published in which mortality data are available for either receipt of ceftazidime alone [3, 9, 10] or receipt of ceftazidime plus TMP-SMX [4, 11] . It is difficult to extrapolate the best practice from these findings, because the ceftazidime monotherapy studies were performed at one center (in Ubon Ratchathani) and the combined regimens were studied at another (in Khon Kaen). A meta-analysis of previous data on the value of TMP-SMX was not feasible because of differences in study design.
In this study, there was no mortality benefit associated with the addition of TMP-SMX to the treatment regimen. With the exception of a switch in therapy ( ), other markers of P p .049 treatment failure were not significantly different between the 2 treatment groups. In a post-hoc analysis adjusting for bacteremia at hospital admission, the P value for a switch in therapy was increased to .08, suggesting that a slight imbalance in initial severity between the treatment groups may, in part, explain this finding.
A prolonged course of oral antibiotic therapy is prescribed after initial parenteral therapy for melioidosis, for a total treatment duration of 12-20 weeks. The rationale for this is that rates of recurrent infection are high (∼6% in the first year), and a treatment duration of !12 weeks is associated with a greater risk of relapse. One issue not addressed by this study is whether the drugs used for initial therapy also affect rate of relapse. It is possible that the drugs used in early disease influence bacterial clearance and the likelihood of persistence, particularly because TMP-SMX has been used successfully in Australia for oral eradication therapy. In view of this, followup of patients in this study continues to define the relapse rate in the 2 groups.
The addition of TMP-SMX to ceftazidime regimens is well tolerated but does not affect mortality related to melioidosis. In this study, the overall mortality rate for severe melioidosis was 21%, which, although still high, is lower than has been reported previously. This may result from general improvements in supportive treatment and from the exclusion of patients with renal failure at one of the study sites. Much of this mortality is due to early fulminant sepsis (40% of deaths occurred within 48 h after commencement of specific antibiotic treatment). Interventions directed at the complications of fulminant sepsis may improve outcomes in the future for patients with melioidosis.
